Loading Events

« All Events

2024 State of Possible Conference

April 24

MassBio’s State of Possible Conference is the premier event for the Massachusetts life sciences industry.

Attendees from the lab to the c-suite will experience a packed, ‘can’t miss’ agenda featuring top pharmaceutical and biotech leaders taking the stage to speak to the conference theme of Meeting the Moment. Experience engaging panel discussions on surviving biotech’s choppy waters and rewriting what is possible in science, with ample time for networking, partnering, and celebrating. New this year – we will recognize MassBio members during an award showcase, including the Henri A. Termeer Innovative Leadership Award, and host a surprise experience designed to “give back” to the community.

Register today to join 500+ attendees from across the ecosystem.

2024 State of Possible Conference Speakers:

  • Devin McCourty, 3x Super Bowl champion and sickle cell disease advocate
  • Governor Maura Healey, Commonwealth of Massachusetts
  • John F. Crowley, President & CEO, Biotechnology Innovation Organization (BIO)
  • Reshma Kewalramani, President & CEO, Vertex Pharmaceuticals
  • Peter Kolchinsky, Managing Partner, RA Capital Management
  • Tess Cameron, Principal, RA Capital Management
  • Susan Windham-Bannister, President & CEO, Biomedical Growth Strategies
  • Kendalle Burlin O’Connell, CEO & President, MassBio
  • Panel discussions
    • Success in Choppy Waters
      • Doug Banks, Executive Editor, Boston Business Journal – Moderator
      • Sharon Cunningham, CEO & Co-Founder, Shorla Oncology
      • Barry Greene, CEO, Sage Therapeutics
      • Mike Nally, CEO, Generate Biomedicines
      • Daphne Zohar, Founder and CEO, PureTech Health
    • Rewriting What is Possible
      • Chris Garabedian, Chairman and CEO, Xontogeny – Moderator
      • Abe Ceesay, CEO, Rapport Therapeutics
      • Emma Lees, Ph.D, Sr. Vice President of Research and Early Development, Bristol Myers Squibb
      • Jacob Sten Petersen, Senior Vice President, Head of Global Nucleic Acid Therapies, Novo Nordisk
      • Stan Wang, MD, Ph.D, CEO & Founder, Thymmune Therapeutics